2.2084

10.02% -0.2116

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is traded at $2.2084, with a volume of 279.19K. It is down -10.02% in the last 24 hours and up +55.54% over the past month. Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Previous Close:

$2.42

Open:

$2.39

24h Volume:

279.19K

Relative Volume:

0.49

Market Cap:

$95.77M

Revenue:

$88.55M

Net Income/Loss:

$-53.21M

P/E Ratio:

-1.7068

EPS:

-1.2939

Net Cash Flow:

$-29.48M

1W Performance:

-4.49%

1M Performance:

+55.54%

6M Performance:

+46.15%

1Y Performance:

+39.59%

1-Day Range:

$2.165

$2.42

1-Week Range:

$2.14

$2.485

52-Week Range:

$1.13

$2.89

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1089)

Industry

Medical Devices (141)

Phone

650-364-0400

Address

700 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

296

Twitter

Next Earnings Date

2026-07-29

Latest SEC Filings

LUNG's Discussions on Twitter

Compare LUNG vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUNG Pulmonx Corp	2.23	103.93M	88.55M	-53.21M	-29.48M	-1.2939
ABT Abbott Laboratories	110.12	192.51B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	332.46	130.11B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	90.66	116.83B	36.36B	4.84B	5.43B	3.7261
BSX Boston Scientific Corp	51.55	75.11B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	90.81	52.80B	6.30B	1.07B	1.09B	1.8406

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-25	Downgrade	Piper Sandler	Overweight → Neutral
Mar-10-25	Initiated	D. Boral Capital	Buy
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Jun-04-24	Initiated	Lake Street	Buy
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

Aug 15, 2026

Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year - MarketBeat

Aug 15, 2026

Aug 14, 2026

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? - Yahoo! Finance Canada

Aug 14, 2026

Aug 13, 2026

Morgan Stanley (LUNG) reports 6.9% Pulmonx stake in updated ownership filing - Stock Titan

Aug 13, 2026

Aug 11, 2026

Pulmonx at Canaccord Genuity growth conference: turnaround gains pace - Investing.com

Aug 11, 2026

Aug 07, 2026

Pulmonx (LUNG) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 07, 2026

Aug 04, 2026

Pulmonx Corp 2026: Revenue $22.76M, EPS ($0.24) — 10-Q Summary - TradingView

Aug 04, 2026

Aug 03, 2026

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Aug 03, 2026

Aug 01, 2026

Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40 - Sahm

Aug 01, 2026

Jul 30, 2026

LUNG Looks 82.5% Undervalued on GF Value™ Despite Financial Chal - GuruFocus

Jul 30, 2026

Pulmonx Target of Unusually Large Options Trading (NASDAQ:LUNG) - MarketBeat

Jul 30, 2026

Jul 29, 2026

Earnings call transcript: Pulmonx tops Q2 2026 estimates, shares jump 14.4% - Investing.com

Jul 29, 2026